TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00609674
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03340376
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin
Study: NCT01058668
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for three weeks.
Study: NCT03437265
Drug: PLENVU powder for oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLENVU Dose 1 (1 sachet) and PLENVU Dose 2 (2 sachets)
Study: NCT00640328
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT00252967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00599079
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin Daily Dosage dependent on clinical factos such as age, weight and patient specific health descriptors
Study: NCT01251107
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 35 mg/2 iv on day 1 during cycles 1 to 4; 25 mg/m2 iv on day 1 during cycles 5 to 8
Study: NCT01251107
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250 mg/m2 iv on day 1 during cycles 1 to 4; 650 mg/m2 iv on day 1 during cycles 5 to 8
Study: NCT01251107
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m2 iv on days 1 and 15 in each cycle
Study: NCT00137111
Drug: Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Detailed Description sections for details on treatment interventions.
Study: NCT00137111
Drug: Methotrexate, Cyclophosphamide, Cytarabine, Etoposide
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Detailed Description sections for details on treatment interventions.
Study: NCT00137111
Drug: Mercaptopurine, Imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Detailed Description sections for details on treatment interventions.
Study: NCT02526004
Drug: Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00888862
Drug: Desvenlafaxine Succinate
Normalized name: Desvenlafaxine Succinate
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desvenlafaxine Succinate, 50-100mg/day for 8 weeks
Study: NCT03152019
Drug: Protopic® (Tacrolimus) 0.1% ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.
Study: NCT03152019
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.
Study: NCT02872207
Drug: BAY 987516 (Y65-122)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 µL in one eye
Study: NCT02872207
Drug: BAY 987516 (Y65-118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 µL in one eye
Study: NCT00003331
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003331
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04312048
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet of placebo vaginally 3 hours prior to copper IUD insertion
Study: NCT00820521
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04687800
Drug: Durezol 0.05% Ophthalmic Emulsion
Normalized name: Durezol 0.05% Ophthalmic Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy, topical steroid drop
Study: NCT03861559
Drug: placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal administration
Study: NCT00782951
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single IV dose of placebo after dental impaction surgery
Study: NCT01156584
Drug: Toca FC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-6 week cycles of Toca FC. Doses evaluated from 120 mg/kg/day or 300 mg/kg/day. Duration of dosing evaluated: 6 days, 7 days or 14 days.
Study: NCT00586261
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 30 mg daily for 6 months
Study: NCT01203384
Drug: CHF5074 1x
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet, 1x, once a day in the morning for 14 days
Study: NCT01203384
Drug: CHF5074 2x
Normalized name: Worm Protector 2X
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet, 2x, once a day in the morning for 14 days
Study: NCT01203384
Drug: CHF5074 3x
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet, 3x, once a day in the morning for 14 days
Study: NCT01203384
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet, placebo, once a day in the morning for 14 days
Study: NCT02834468
Drug: DEX Combined With RTX, CSA and IVIG
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigators are undertaking a multicenter trial of 100 primary ITP adult patients from 5 medical centers in China. All participants receive dexamethasone (given orally at a dose of 40 mg per day for 4 days), rituximab (given intravenously at a dose of 500mg once), cyclosporin (given orally at a dose of 2.5-3 mg/kg per day for 28 days) and intravenous immunoglobulin (given intravenously at a dose of 5g per month for 6 months) for the treatment of adults newly diagnosed ITP patients.
Study: NCT03339661
Drug: Group 1_No proph treatment
Normalized name: no 'zit' sherlock spot treatment 2 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the curative treatment of CMV infection until a negative CMV ADNemia, secondary prophylaxis with valganciclovir will be established based on the results of γδ T cells immunomonitoring. In this group, expansion of γδ T cell at the end curative treatment was detected, so secondary prophylaxis will not be started.
Study: NCT01663233
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 will use tablets available at a strength of 200mg. Patients will be instructed to take the prescribed medication once a day.
Study: NCT01663233
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to LCZ696
Study: NCT02321098
Drug: Loceryl NL 12 weeks
Normalized name: glyceryl 1,2-dioleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loceryl NL once/week for 12 weeks
Study: NCT02222207
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo eye drops
Study: NCT03343587
Drug: LY3375880 IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered IV
Study: NCT03343587
Drug: LY3375880 SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered SC
Study: NCT03343587
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered IV
Study: NCT03343587
Drug: Placebo SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered SC
Study: NCT00622648
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)
Study: NCT02187471
Drug: DS-5565
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-5565 15 mg QD or BID; tablet for oral use
Study: NCT02187471
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet for oral use, matching DS-5565 tablet
Study: NCT00522431
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2% gel
Study: NCT00004231
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004231
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004231
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004231
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03388853
Drug: Acetylcysteine/Doxofylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet once daily for four weeks.
Study: NCT03285594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Study: NCT00665457
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00665457
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00665457
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00665457
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03285594
Drug: Oral Antidiabetes Drugs (OADs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OADs (including metformin) as prescribed by the investigator as per local labeling.
Study: NCT04195321
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: infusion will be started after induction of spinal anesthesia
Study: NCT02325219
Drug: CTNO 1959 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive subcutaneous injection of CNTO 1959 100 mg.
Study: NCT02325219
Drug: Placebo 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 50 mg.
Study: NCT02325219
Drug: Placebo 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 100 mg.
Study: NCT01525004
Drug: High-Dose trivalent inactivated influenza vaccine
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
Study: NCT01525004
Drug: Standard dose trivalent inactivated influenza vaccine
Normalized name: diphtheria toxoid vaccine, inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL standard dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine
Study: NCT00935168
Drug: 6% Hydroxy-ethyl starch (130/0.4)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximum dose of 50ml/kg/day of 6% hydroxy-ethyl starch (130/0.4) for intravascular volume fluid resuscitation
Study: NCT00878020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, 0mg, Single Dose, 1 day
Study: NCT00878020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, 0mg, Single Dose, on Day 1, Period 1 and Day 1, Period 2, 2 days
Study: NCT03551444
Drug: Administration of DAA-based treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Antiviral therapy and treatment duration (12/24 weeks) will be indicated in each patient according to the viral genotype/subtype and the severity of liver disease, in accordance with the EASL Recommendations on Treatment of Hepatitis C 2016.~* HCV-RNA quantification will be assessed by real-time PCR, with a limit of detection (LOD) of15 IU/mL.~* During antiviral treatment, follow-up of the Patients will be monthly by clinical and laboratory evaluation.~* Virological response to DAA-based treatment will be assessed by quantitative HCV-RNA at the end of treatment (EOT) and at 4 and 12 weeks after the EOT, to confirm sustained virological response (SVR).~* SVR12 is defined as undetectable HCV-RNA at week 12 after the EOT.~* Virological failures and early discontinuations of therapy due to adverse events will be also registered.
Study: NCT01263171
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01263171
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01263171
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01652183
Drug: intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03165097
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules matching ACT-709478 capsules
Study: NCT03588923
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, oral, once daily for 3 days
Study: NCT05220527
Drug: vitagen plus hyruan
Approvals — FDA: no, EMA: no, PMDA: no
Description: vitagen plus hyruan injections, one time per week, for 3 weeks
Study: NCT02669017
Drug: ADCT-402
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT02313155
Drug: Subcutaneous injection of TAK-850
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-850 0.5 mL, Subcutaneous injection
Study: NCT02313155
Drug: Intramuscular injection of TAK-850
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-850 0.5 mL, Intramuscular injection
Study: NCT03385564
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT00932347
Drug: Camellia sinensis mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: mouthrinsing, 2 times/day, for 28 days
Study: NCT00932347
Drug: Placebo mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: mouthrinsing, 2 times/day, for 28 days
Study: NCT00466167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03199963
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An absorptive hydroalcoholic gel preparation of the same ingredients as BHR-700, but without 4-OHT.
Study: NCT00836849
Drug: Zoloft® 100 mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 100 mg, single-dose fed
Study: NCT00223925
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00868413
Drug: ABT-263
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-263 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
Study: NCT00404014
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose of placebo
Study: NCT00691964
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ placebo injections for ABT-874 and etanercept
Study: NCT00097760
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, by IV infusion, every 4 weeks in addition to 20 mg glatiramer acetate, by SC injection, daily, for up to 20 weeks.
Study: NCT01478035
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin 18 mg /Kg/day iv as loading dose. 24 hours later phenytoin 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.
Study: NCT03778619
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administration of fludarabine 250mg/m2 for 3 consecutive days starting at 3 days before the 1st, 3rd, and 5th cycle of the first rituximab infusion for that cycle
Study: NCT00037180
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00037180
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04609852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion.
Study: NCT02640417
Drug: B Vitamins
Normalized name: B-50 Hi Potency B Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment with vitamins B1, B6, and B12
Study: NCT00864435
Drug: Coreg® 12.5 mg Tablets , single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fasting conditions
Study: NCT00663065
Drug: PAZ-417
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03393208
Drug: Test GIR
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received 500 milligrams (mg) test GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
Study: NCT03393208
Drug: Reference GIR
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received 500 mg reference GIR in fasting or fed state on either Day 1 (Treatment Period 1) or Day 8 (Treatment Period 2).
Study: NCT01947920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Size-matching capsules containing an appropriate inactive excipient
Study: NCT00418145
Drug: megadose oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1400 mg qd/5 days
Study: NCT00418145
Drug: IV methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000 mg/qd/5 days
Study: NCT00840411
Drug: Clarithromycin ER 500 mg tablets
Normalized name: clarithromycin Extended Release Oral Tablet
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 500 mg
Study: NCT00840411
Drug: BIAXIN® XL 500 mg tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 500 mg
Study: NCT00833937
Drug: AMBIEN® 10 mg tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 10 mg
Study: NCT03106038
Drug: Nerindocianine for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procedure: routine minimally invasive pelvic surgery.
Study: NCT00807794
Drug: MEDI-507
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.012 mg/kg dose given twice between 60 to 72 hours apart
Study: NCT00807794
Drug: MEDI-507
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06 mg/kg dose given twice between 60 to 72 hours apart
Study: NCT02141711
Drug: TAK-438 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-438 placebo-matching tablets
Study: NCT00023374
Drug: REZ
Normalized name: Breze
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rif+PZA+EMB given 2 or 3 times weekly for 6 months
Study: NCT00807794
Drug: MEDI-507
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12 mg/kg dose given twice between 60 to 72 hours apart
Study: NCT00807794
Drug: MEDI-507
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.24 mg/kg dose given twice between 60 to 72 hours apart (supplemental)
Study: NCT03134352
Drug: ZL-3101
Approvals — FDA: no, EMA: no, PMDA: no
Description: A brown ointment, 10g/tube, 0.4g herb/g ointment, Topical
Study: NCT00835536
Drug: COPEGUS™ 200 mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 200 mg, single-dose non-fasting
Study: NCT03134352
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A brown ointment, 10g/tube, 0.02 g herb/g ointment (5% of Fugan active ointment), Topical
Study: NCT02137954
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03173547
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream does not contain an active drug and is applied topically.
Study: NCT02599701
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single placebo dose with the same physical characteristics of the active intervention.
Study: NCT01951820
Drug: Benzocaine
Normalized name: Benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apply 0.2mg of topical anesthetic (benzocaine) to gums for 2.5 minutes before giving patient injection of local anesthetic.
Study: NCT01788254
Drug: Codeine
Normalized name: Codeine
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
Study: NCT01788254
Drug: pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
Study: NCT02749890
Drug: Oral anti-diabetic drugs
Normalized name: Diabetic Tussin EX Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: Oral
Study: NCT02364089
Drug: Standardized medical treatment of hypertension by SAHR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized anti-hypertensive drug regimen has been established according to international recommendations and includes the following steps:~* step 1: Angiotensin converting enzyme inhibitor (ACE-I) or angiotensin II receptor antagonist (ARBs) at half-dose (Ranipril 5mg or Ibesartan 150 mg )~* step 2: CEI or ARA2 at full dose (Ranipril 10 mg or Ibesartan 300 mg)~* step 3: Add-on of Amlodipine 10 mg or Diltiazem LP 300 mg~* step 4: Add-on of Indapamide LP 1.5 mg~* step 5: Add-on of Spironolactone 25 mg~* step 6: Add-on of Bisoprolol 10 mg~* step 7: Add-on of Prazosine LP 5mg/day.
Study: NCT01445821
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: An alkylating agent which causes prevention of cell division by forming adducts with DNA
Study: NCT00531752
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage Form: matching placebo capsules Dosage: Subjects will take two placebo capsules each morning throughout the 3 week double-blind treatment placebo treatment period.
Study: NCT00326352
Drug: Sedation with propofol and remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00619073
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus aspirin 81 mg, tablet by mouth daily for 14 days.